IL177544A - Sulfur compounds, enantiomers, stereoisomers, rotamers, tautomers and their radicals and their use in the preparation of drugs for the treatment of hcv-related disorders - Google Patents
Sulfur compounds, enantiomers, stereoisomers, rotamers, tautomers and their radicals and their use in the preparation of drugs for the treatment of hcv-related disordersInfo
- Publication number
- IL177544A IL177544A IL177544A IL17754406A IL177544A IL 177544 A IL177544 A IL 177544A IL 177544 A IL177544 A IL 177544A IL 17754406 A IL17754406 A IL 17754406A IL 177544 A IL177544 A IL 177544A
- Authority
- IL
- Israel
- Prior art keywords
- streoisomers
- rotamers
- hcv
- racemates
- tautomers
- Prior art date
Links
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000003464 sulfur compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54867004P | 2004-02-27 | 2004-02-27 | |
| PCT/US2005/005795 WO2005087731A1 (en) | 2004-02-27 | 2005-02-24 | Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL177544A0 IL177544A0 (en) | 2006-12-10 |
| IL177544A true IL177544A (en) | 2015-02-26 |
Family
ID=34961556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL177544A IL177544A (en) | 2004-02-27 | 2006-08-17 | Sulfur compounds, enantiomers, stereoisomers, rotamers, tautomers and their radicals and their use in the preparation of drugs for the treatment of hcv-related disorders |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8067379B2 (enExample) |
| EP (1) | EP1730110B9 (enExample) |
| JP (1) | JP4714732B2 (enExample) |
| KR (2) | KR101316137B1 (enExample) |
| CN (2) | CN101076516A (enExample) |
| AR (1) | AR048241A1 (enExample) |
| AT (1) | ATE470660T1 (enExample) |
| AU (1) | AU2005222060A1 (enExample) |
| BR (1) | BRPI0508085A (enExample) |
| CA (1) | CA2557495C (enExample) |
| CY (1) | CY1111212T1 (enExample) |
| DE (1) | DE602005021760D1 (enExample) |
| DK (1) | DK1730110T3 (enExample) |
| EC (1) | ECSP066791A (enExample) |
| ES (1) | ES2346233T3 (enExample) |
| HR (1) | HRP20100416T1 (enExample) |
| IL (1) | IL177544A (enExample) |
| MY (1) | MY145081A (enExample) |
| NO (1) | NO20064358L (enExample) |
| NZ (1) | NZ549223A (enExample) |
| PE (1) | PE20051150A1 (enExample) |
| PL (1) | PL1730110T3 (enExample) |
| PT (1) | PT1730110E (enExample) |
| RS (1) | RS51394B (enExample) |
| RU (1) | RU2428428C9 (enExample) |
| SG (1) | SG186041A1 (enExample) |
| SI (1) | SI1730110T1 (enExample) |
| TW (2) | TWI314927B (enExample) |
| WO (1) | WO2005087731A1 (enExample) |
| ZA (1) | ZA200607096B (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN183120B (enExample) | 1996-10-18 | 1999-09-11 | Vertex Pharma | |
| ATE470660T1 (de) * | 2004-02-27 | 2010-06-15 | Schering Corp | Schwefelverbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus |
| US7816326B2 (en) * | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| GB0426661D0 (en) * | 2004-12-06 | 2005-01-05 | Isis Innovation | Pyrrolidine compounds |
| US20060276406A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| US20060276407A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| AU2006252623A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis C virus |
| EP1919478B1 (en) * | 2005-06-02 | 2016-03-23 | Merck Sharp & Dohme Corp. | Combination of hcv protease inhibitors with a surfactant |
| WO2006130626A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
| US20060276404A1 (en) * | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
| NZ563361A (en) | 2005-06-02 | 2011-02-25 | Schering Corp | HCV protease inhibitors in combination with food |
| US20070021351A1 (en) * | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| US20060275366A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| WO2007106317A2 (en) * | 2006-03-03 | 2007-09-20 | Schering Corporation | Pharmaceutical combinations of hcv-protease and -ires inhibitors |
| KR101398259B1 (ko) | 2006-03-16 | 2014-05-26 | 버텍스 파마슈티칼스 인코포레이티드 | 입체 화합물의 제조 방법 및 이를 위한 중간체 |
| CA2647158C (en) * | 2006-03-23 | 2012-07-31 | Schering Corporation | Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto |
| US7825152B2 (en) | 2006-04-11 | 2010-11-02 | Novartis Ag | Organic compounds and their uses |
| DE102006059317A1 (de) | 2006-07-04 | 2008-01-10 | Evonik Degussa Gmbh | Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden |
| MX2009000882A (es) | 2006-08-17 | 2009-02-04 | Boehringer Ingelheim Int | Inhibidores de la polimerasa virica. |
| US20100081672A1 (en) * | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
| MX2009006878A (es) | 2006-12-22 | 2009-07-07 | Schering Corp | Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas. |
| US8268803B2 (en) | 2006-12-22 | 2012-09-18 | Merck Sharp & Dohme Corp. | 5, 6-ring annulated indole derivatives and use thereof |
| KR20090094154A (ko) | 2006-12-22 | 2009-09-03 | 쉐링 코포레이션 | Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체 |
| WO2008078563A1 (ja) * | 2006-12-22 | 2008-07-03 | Sumitomo Seika Chemicals Co., Ltd. | ３－ベンジルオキシベンゼンチオールの製造方法 |
| EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | VIRAL POLYMERASE HEMMER |
| TW200924751A (en) | 2007-08-29 | 2009-06-16 | Schering Corp | 2,3-substituted indole derivatives and methods of use thereof |
| CN101821252A (zh) | 2007-08-29 | 2010-09-01 | 先灵公司 | 取代的吲哚衍生物及其使用方法 |
| KR20100065167A (ko) | 2007-08-29 | 2010-06-15 | 쉐링 코포레이션 | 바이러스 감염 치료용 2,3-치환된 아자인돌 유도체 |
| NZ583825A (en) * | 2007-09-14 | 2012-06-29 | Schering Corp | Method of treating hepatitis C patients comprising an HCV protease inhibitor, an antiviral compound and an interferon |
| CN101868452B (zh) | 2007-10-10 | 2014-08-06 | 诺华股份有限公司 | 螺环吡咯烷类与其对抗hcv和hiv感染的应用 |
| US8765757B2 (en) | 2007-11-16 | 2014-07-01 | Merck Sharp & Dohme Corp. | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| MX2010005355A (es) | 2007-11-16 | 2010-06-02 | Schering Corp | Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos. |
| US8476257B2 (en) | 2007-12-19 | 2013-07-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7964560B2 (en) * | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2010013630A (es) | 2008-06-13 | 2010-12-21 | Schering Corp | Derivados triciclicos de indol y metodos de uso de los mismos. |
| WO2010017432A1 (en) * | 2008-08-07 | 2010-02-11 | Schering Corporation | Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion |
| US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| AR074582A1 (es) | 2008-12-12 | 2011-01-26 | Schering Corp | Compuestos deuterados como inhibidores del virus de la hepatitis c (hcv) |
| MX2011007195A (es) | 2009-01-07 | 2013-07-12 | Scynexis Inc | Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih). |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| EP2435424B1 (en) | 2009-05-29 | 2015-01-21 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| EP2459525B1 (en) * | 2009-07-29 | 2017-03-01 | Merck Sharp & Dohme Corp. | Enantio- and stereo-specific syntheses of -amino- - hydroxy amides |
| US20120276047A1 (en) | 2009-11-25 | 2012-11-01 | Rosenblum Stuart B | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| EP2516430B1 (en) | 2009-12-22 | 2014-11-05 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| BR112012022125A2 (pt) | 2010-03-09 | 2016-11-01 | Merck Sharp & Dhme Corp | composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente |
| JP2013541499A (ja) | 2010-07-26 | 2013-11-14 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法 |
| US9133116B2 (en) | 2010-09-28 | 2015-09-15 | Panacea Biotec Ltd. | Bicyclic compounds |
| AU2011314168A1 (en) | 2010-09-29 | 2013-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012073249A1 (en) | 2010-12-01 | 2012-06-07 | Arch Pharmalabs Limited | A novel process for the preparation of 3-(benzyloxy)- benzenethiol, a key intermediate for the preparation of pharmaceutical drugs. |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EA201391519A1 (ru) | 2011-04-13 | 2014-03-31 | Мерк Шарп И Доум Корп. | 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний |
| WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| EP2755981A4 (en) | 2011-09-14 | 2015-03-25 | Merck Sharp & Dohme | SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES |
| US10167298B2 (en) | 2013-10-30 | 2019-01-01 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof |
| WO2017059446A1 (en) * | 2015-10-01 | 2017-04-06 | Memorial Sloan-Kettering Cancer Center | Anthranilyl-adenosinemonosulfamate analogs and uses thereof |
| CA3000709A1 (en) * | 2015-10-01 | 2017-04-06 | Memorial Sloan-Kettering Cancer Center | Inhibitors of menaquinone biosynthesis |
| EA201990070A1 (ru) | 2016-06-21 | 2019-06-28 | ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи | Производные алифатического пролинамида |
| US12435088B2 (en) | 2018-12-21 | 2025-10-07 | Memorial Sloan-Kettering Cancer Center | Salicyl-adenosinemonosulfamate analogs and uses thereof |
| WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
| EP4653420A1 (en) | 2023-01-17 | 2025-11-26 | Shenyang Haisco Pharmaceutical Co., Ltd. | Method for preparing chiral amino alcohol pharmaceutical intermediates |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69133617D1 (de) | 1990-04-04 | 2009-07-23 | Novartis Vaccines & Diagnostic | Protease von Hepatitis C Virus |
| US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
| IN183120B (enExample) | 1996-10-18 | 1999-09-11 | Vertex Pharma | |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| PT1012180E (pt) | 1997-08-11 | 2005-04-29 | Boehringer Ingelheim Ca Ltd | Analogos de peptidos inibidores da hepatite c |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| JP4806154B2 (ja) | 2000-04-03 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター |
| NZ521455A (en) | 2000-04-05 | 2004-06-25 | Schering Corp | Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising N-Cyclic P2 Moieties |
| BR0110104A (pt) | 2000-04-19 | 2003-01-07 | Schering Corp | Inibidores de ns-3 serina rotease macrocìclica do vìrus da hepatite c compreendendo porções de alquil e aril alanina p2 |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| WO2002008251A2 (en) | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| MY139078A (en) | 2000-07-21 | 2009-08-28 | Schering Corp | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| WO2002008187A1 (en) | 2000-07-21 | 2002-01-31 | Schering Corporation | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| EP1343807B1 (en) | 2000-12-12 | 2009-04-29 | Schering Corporation | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
| WO2003035060A1 (en) * | 2001-10-24 | 2003-05-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
| US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| ATE470660T1 (de) * | 2004-02-27 | 2010-06-15 | Schering Corp | Schwefelverbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus |
| EP1919478B1 (en) | 2005-06-02 | 2016-03-23 | Merck Sharp & Dohme Corp. | Combination of hcv protease inhibitors with a surfactant |
-
2005
- 2005-02-24 AT AT05723607T patent/ATE470660T1/de active
- 2005-02-24 PE PE2005000220A patent/PE20051150A1/es not_active Application Discontinuation
- 2005-02-24 SI SI200531086T patent/SI1730110T1/sl unknown
- 2005-02-24 AU AU2005222060A patent/AU2005222060A1/en not_active Abandoned
- 2005-02-24 MY MYPI20050737A patent/MY145081A/en unknown
- 2005-02-24 SG SG2012087664A patent/SG186041A1/en unknown
- 2005-02-24 JP JP2007500955A patent/JP4714732B2/ja not_active Expired - Fee Related
- 2005-02-24 TW TW094105518A patent/TWI314927B/zh not_active IP Right Cessation
- 2005-02-24 HR HR20100416T patent/HRP20100416T1/hr unknown
- 2005-02-24 ES ES05723607T patent/ES2346233T3/es not_active Expired - Lifetime
- 2005-02-24 CA CA2557495A patent/CA2557495C/en not_active Expired - Fee Related
- 2005-02-24 AR ARP050100679A patent/AR048241A1/es not_active Application Discontinuation
- 2005-02-24 DE DE602005021760T patent/DE602005021760D1/de not_active Expired - Lifetime
- 2005-02-24 PT PT05723607T patent/PT1730110E/pt unknown
- 2005-02-24 WO PCT/US2005/005795 patent/WO2005087731A1/en not_active Ceased
- 2005-02-24 CN CNA2005800128593A patent/CN101076516A/zh active Pending
- 2005-02-24 PL PL05723607T patent/PL1730110T3/pl unknown
- 2005-02-24 KR KR1020067017257A patent/KR101316137B1/ko not_active Expired - Fee Related
- 2005-02-24 RS RSP-2010/0360A patent/RS51394B/sr unknown
- 2005-02-24 RU RU2006134003/04A patent/RU2428428C9/ru active
- 2005-02-24 EP EP05723607A patent/EP1730110B9/en not_active Expired - Lifetime
- 2005-02-24 NZ NZ549223A patent/NZ549223A/en not_active IP Right Cessation
- 2005-02-24 BR BRPI0508085-1A patent/BRPI0508085A/pt not_active IP Right Cessation
- 2005-02-24 DK DK05723607.7T patent/DK1730110T3/da active
- 2005-02-24 CN CN2012103533032A patent/CN103102389A/zh active Pending
- 2005-02-24 TW TW098107879A patent/TWI393704B/zh not_active IP Right Cessation
- 2005-02-24 US US11/064,673 patent/US8067379B2/en active Active
- 2005-02-24 KR KR1020127034290A patent/KR20130018418A/ko not_active Withdrawn
-
2006
- 2006-08-17 IL IL177544A patent/IL177544A/en not_active IP Right Cessation
- 2006-08-24 ZA ZA200607096A patent/ZA200607096B/xx unknown
- 2006-08-25 EC EC2006006791A patent/ECSP066791A/es unknown
- 2006-09-26 NO NO20064358A patent/NO20064358L/no not_active Application Discontinuation
-
2010
- 2010-09-01 CY CY20101100796T patent/CY1111212T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL177544A (en) | Sulfur compounds, enantiomers, stereoisomers, rotamers, tautomers and their radicals and their use in the preparation of drugs for the treatment of hcv-related disorders | |
| IL177717A0 (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
| ZA200606056B (en) | Selected CGRP antagonists, methods for the production thereof and their use as medicaments | |
| IL212396A (en) | 6-oxo-1,6-dihydropyridazines and their use in drug preparation | |
| SI1725253T1 (sl) | Zdravila in metode za zdravljenje glavobola | |
| IL184694A0 (en) | New polymorphous forms of rifazimin, processes for their production and use thereof in the medicinal | |
| GB2434604B (en) | Porous composites containing hydrocarbon-soluble well treatment agents and methods for using the same | |
| IL181012A0 (en) | Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments | |
| EP1827450A4 (en) | METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE | |
| ZA200710713B (en) | Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives | |
| IL181964A0 (en) | Medicaments comprising carbonyl compounds, and the use thereof | |
| IL202424A (en) | Telomerase activator compounds for use in the treatment of disorders and related conditions | |
| IL225911A (en) | Citrulline preparations for use in the treatment of asthma | |
| ZA200800431B (en) | Selected cgrp antagonists, methods for the production thereof and their use as medicaments | |
| ZA200701193B (en) | The use of N-aryl diazaspiracyclic compounds in the treatment of addiction | |
| IL187235A0 (en) | 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament | |
| IL189497A0 (en) | Selected cgrp antagonists, methods for the production thereof and their use as medicaments | |
| EP1741746A4 (en) | METHOD OF MANUFACTURING RUBBER COMPOSITION, RUBBER COMPOSITION AND USE THEREOF | |
| IL182356A0 (en) | Novel cyclic and acyclic propenones and their use in the preparation of medicaments for treating cns disorders | |
| TWI367222B (en) | Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof | |
| IL179670A0 (en) | Heterocyclic compounds and processes for the preparation thereof | |
| EP1968645A4 (en) | HUMAN GLP-1 MIMETIC BODIES AND COMPOSITIONS FOR THE TREATMENT OF ADIPOSITAS AND RELATED DISEASES, METHODS AND APPLICATIONS | |
| TWI350753B (en) | 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain | |
| ZA200703883B (en) | Carbamate compounds for use in treating neurodegenerative disorders | |
| PL1732557T3 (pl) | Pochodne 1-[2H-1-benzopiran-2-on-8-ylo]-piperazyny do leczenia zaburzeń ruchowych |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |